The recommendations cover DPP-4 inhibitors (sitagliptin and vildagliptin), glitazones (pioglitazone and rosiglitazone) and exenatide, as well as when to start insulin therapy.
Metformin and a sulphonylurea remain preferred first- and second-line agents, but for patients not suitable for this treatment and who are uncontrolled on one of them, a DPP-4 inhibitor or a glitazone is recommended as an add-on therapy.
Exenatide can be added to metformin and a sulphonylurea for obese patients and those unsuitable for insulin therapy.
Comment below and tell us what you think
